Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
1.
Public Health ; 180: 141-148, 2020 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-31918048

RESUMEN

OBJECTIVES: Germany has a mandatory surveillance system for acute hepatitis B (AHB) with the Protection against Infection Act as the legal basis in place since 2001. An amendment was introduced in 2013. We aimed at evaluating the surveillance systems' performance regarding timeliness, data quality, and simplicity from 2005 to 2014 and at assessing the effect of the amendment on timeliness of AHB surveillance. STUDY DESIGN: This study is a trend analysis of surveillance data. METHODS: Aspects of simplicity versus complexity of the surveillance system were assessed by describing data flow, levels of reporting, and data management procedures. Data quality, in terms of data completeness, was evaluated by quantitative indicators, and timeliness was measured in days between different levels of the surveillance system, notification delay, and reporting delay. Trends over time in data quality were analyzed by logistic regression, while negative binomial regression was used to test for trend over time regarding mean notification and reporting delay. RESULTS: Between January 2005 and December 2014, a total of 22,549 AHB infections were reported at the national level. The data flow of the German AHB surveillance system showed structural characteristics of a complex system. Over the 10-year period, completeness of reporting sex, age, probable route of transmission, and hepatitis B virus (HBV) vaccination were 99%, 100%, 25%, and 73%, respectively. However, data quality decreased over the evaluation period. Although notification delay improved over time (incident rate ratio [IRR] = 0.95, 95% confidence interval [CI] = 0.95-0.96; P < 0.05), reporting delay improved only since the amendment (IRR = 0.76, 95% CI = 0.70-0.82; P < 0.05). In total, mean notification and reporting delay were 3.0 days and 14.3 days, respectively. CONCLUSIONS: The German AHB surveillance system is operating in a timely manner. Although timeliness improved over the evaluation period and the amendment to the Protection against Infection Act succeeded in reducing reporting time, data quality in terms of completeness of information decreased considerably. As improved data completeness is required to adequately design prevention activities, reasons for this decrease should further be explored.


Asunto(s)
Hepatitis B/epidemiología , Vigilancia de la Población/métodos , Exactitud de los Datos , Notificación de Enfermedades/estadística & datos numéricos , Alemania/epidemiología , Humanos , Factores de Tiempo
2.
Pneumologie ; 70(4): 250-76, 2016 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-27064418

RESUMEN

Non-tuberculous mycobacterioses comprise a group of diseases caused by mycobacteria which do not belong to the Mycobacterium (M.) tuberculosis-complex and are not ascribed to M. leprae. These mycobacteria are characterized by a broad variety as to environmental distribution and adaptation. Some of the species may cause specific diseases, especially in patients with underlying immunosuppressive diseases, chronic pulmonary diseases or genetic predisposition, respectively. Worldwide, a rising prevalence and significance of non-tuberculous mycobacterioses is recognized. The present recommendations summarise current aspects of epidemiology, pathogenesis, clinical aspects, diagnostics - especially microbiological methods including susceptibility testing -, and specific treatment for the most relevant species. Diagnosis and treatment of non-tuberculous mycobacterioses during childhood and in HIV-infected individuals are described in separate chapters.


Asunto(s)
Técnicas de Diagnóstico del Sistema Respiratorio/normas , Infectología/normas , Infecciones por Mycobacterium no Tuberculosas/diagnóstico , Infecciones por Mycobacterium no Tuberculosas/terapia , Guías de Práctica Clínica como Asunto , Neumología/normas , Medicina Basada en la Evidencia , Alemania , Humanos , Infecciones por Mycobacterium no Tuberculosas/microbiología , Resultado del Tratamiento
3.
Zentralbl Chir ; 127(10): 850-4, 2002 Oct.
Artículo en Alemán | MEDLINE | ID: mdl-12410450

RESUMEN

UNLABELLED: At our institution we have used fresh-frozen allografts for the reconstruction of the anterior and posterior cruciate ligament since 1993. METHOD: In this retrospective study we evaluated the clinical outcome of 325 fresh-frozen allografts (bone-patellar-tendon-bone allografts and Achilles-bone-tendon allografts) for primary and revision ACL-reconstruction. Patients (average age 38 years) were operated between 5/1993 and 2/1998 and mean follow-up was 38 (range 24 to 71) months. Clinical evaluation consisted of a case history, an examination, IKDC, Cincinnati knee score (CKS), KT-1000 testing and standardized X-rays. RESULTS: Overall subjective rating according to the CKS was more than 82 points for both groups. Objective results according to the IKDC were normal or nearly normal in 75.6 % of primary- and 67.0 % of revision-ACL reconstructions. The stability measured with the KT-1000 showed an average maximum side to side difference of 2.1 mm for primary ACL reconstruction and 2.3 mm for revisioners. The total failure-rate (= rerupture-rate + laxity-failures) was 13.7 % for primary and 15.0 % for revision ACL reconstructions. CONCLUSION: Given the increased failure-rate, autograft tissue remains our graft of first choice for primary ACL-reconstruction. We advise to reserve allografts for revision procedures where suitable autogenous tissues have been previously compromised, where a contraindication for autogenous tissue harvest exists or for multiple ligament surgery. No specific complications were observed with the use of allograft tissue.


Asunto(s)
Lesiones del Ligamento Cruzado Anterior , Trasplante Óseo/métodos , Traumatismos de la Rodilla/cirugía , Complicaciones Posoperatorias/cirugía , Transferencia Tendinosa/métodos , Adolescente , Adulto , Anciano , Ligamento Cruzado Anterior/cirugía , Femenino , Estudios de Seguimiento , Humanos , Masculino , Persona de Mediana Edad , Complicaciones Posoperatorias/etiología , Recurrencia , Reoperación , Estudios Retrospectivos , Trasplante Homólogo
4.
J Immunol ; 166(4): 2801-7, 2001 Feb 15.
Artículo en Inglés | MEDLINE | ID: mdl-11160347

RESUMEN

The acute-phase reactant rabbit serum amyloid A 3 (SAA3) was identified as the major difference product in Ag-induced arthritis in the rabbit, a model resembling in many aspects the clinical characteristics of rheumatoid arthritis (RA) in humans. In Ag-induced arthritis, up-regulated SAA3 transcription in vivo was detected in cells infiltrating into the inflamed joint, in the area where pannus formation starts and, most notably, also in chondrocytes. The proinflammatory cytokine IL-1beta induced SAA3 transcription in primary rabbit chondrocytes in vitro. Furthermore, rSAA3 protein induced transcription of matrix metalloproteinases in rabbit chondrocytes in vitro. In the human experimental system, IL-1beta induced transcription of acute-phase SAA (A-SSA; encoded by SAA1/SAA2) in primary chondrocytes. Similar to the rabbit system, recombinant human A-SAA protein was able to induce matrix metalloproteinases' transcription in chondrocytes. Further, immunohistochemistry demonstrated that A-SAA was highly expressed in human RA synovium. A new finding of our study is that A-SSA expression was also detected in cartilage in osteoarthritis. Our data, together with previous findings of SAA expression in RA synovium, suggest that A-SAA may play a role in cartilage destruction in arthritis.


Asunto(s)
Artritis Reumatoide/enzimología , Metaloproteinasas de la Matriz/metabolismo , Proteína Amiloide A Sérica/biosíntesis , Transcripción Genética , Regulación hacia Arriba , Secuencia de Aminoácidos , Animales , Artritis Reumatoide/inmunología , Artritis Reumatoide/metabolismo , Artritis Reumatoide/patología , Cartílago Articular/metabolismo , Movimiento Celular/genética , Condrocitos/enzimología , Condrocitos/metabolismo , Condrocitos/patología , Modelos Animales de Enfermedad , Femenino , Regulación de la Expresión Génica , Humanos , Interleucina-1/farmacología , Metaloproteinasas de la Matriz/biosíntesis , Metaloproteinasas de la Matriz/genética , Datos de Secuencia Molecular , ARN Mensajero/biosíntesis , Conejos , Proteínas Recombinantes/biosíntesis , Proteínas Recombinantes/aislamiento & purificación , Proteínas Recombinantes/farmacología , Proteína Amiloide A Sérica/genética , Proteína Amiloide A Sérica/aislamiento & purificación , Proteína Amiloide A Sérica/fisiología , Membrana Sinovial/enzimología , Membrana Sinovial/inmunología , Membrana Sinovial/metabolismo , Membrana Sinovial/patología , Transcripción Genética/inmunología , Factor de Necrosis Tumoral alfa/farmacología , Regulación hacia Arriba/genética , Regulación hacia Arriba/inmunología
5.
Aliment Pharmacol Ther ; 13(11): 1531-4, 1999 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-10571612

RESUMEN

OBJECTIVES: To compare testing for Helicobacter pylori IgG antibodies using a dried plasma collection card device with specimens obtained by venepuncture. METHODS: Eighty-four patients underwent testing for H. pylori IgG antibodies by venepuncture and by fingerstick using a single drop of blood placed on each of two dried plasma collection card devices. The correlation of venepuncture results to dried plasma card results was assessed. RESULTS: There was a high degree of correlation of EIA results between venepuncture and dried plasma card specimens (r=0.98). The qualitative result of the first dried plasma card and venepuncture specimen testing differed in 7 of 84 patients and for the second dried plasma card differed in 7 of 82 patients. The first dried plasma card was 93% sensitive and 100% specific and the second was 93% sensitive and 98% specific as compared to the venepuncture result. There was a high degree of correlation between the first and second dried plasma cards (r=0.996). CONCLUSIONS: The dried plasma collection card has adequate sensitivity and excellent specificity as compared to venepuncture specimens and is a feasible alternative for H. pylori IgG antibody testing.


Asunto(s)
Infecciones por Helicobacter/sangre , Infecciones por Helicobacter/diagnóstico , Helicobacter pylori , Plasma/química , Anticuerpos Antibacterianos/análisis , Recolección de Muestras de Sangre , Ensayo de Inmunoadsorción Enzimática , Femenino , Humanos , Inmunoglobulina G/análisis , Masculino , Persona de Mediana Edad , Reproducibilidad de los Resultados , Fumar
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA